Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Costs and Expenses:
General and administrative	$ 2,095	$ 1,604	$ 6,668	$ 5,539
Research and development	7,061	10,046	22,380	24,048
Total Operating Costs and Expenses	9,156	11,650	29,048	29,587
Loss from Operations	(9,156)	(11,650)	(29,048)	(29,587)
Other Income (Expense):
Change in fair value of warrant liability	666	4,141	3,681	(3,906)
Interest income	1	2	36	5
Total Other Income (Expense)	667	4,143	3,717	(3,901)
Net Loss	(8,489)	(7,507)	(25,331)	(33,488)
Net Loss Attributable to Non-controlling Interest	(136)	(733)	(451)	(733)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (8,353)	$ (6,774)	$ (24,880)	$ (32,755)
Net Loss Per Share - Basic	$ (0.09)	$ (0.08)	$ (0.27)	$ (0.42)
Net Loss Per Share - Dilutive	$ (0.09)	$ (0.12)	$ (0.27)	$ (0.42)
Weighted average number of shares outstanding during the period - Basic	91,441,687	85,974,751	91,095,990	77,300,375
Weighted average number of shares outstanding during the period - Dilutive	91,441,687	87,585,103	91,095,990	77,300,375